Hematologic Malignancy Clinical Trials

78 recruitingLast updated: June 17, 2026

There are 78 actively recruiting hematologic malignancy clinical trials across 21 countries. Studies span Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3. Top locations include Boston, Massachusetts, United States, Memphis, Tennessee, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Hematologic Malignancy Trials at a Glance

78 actively recruiting trials for hematologic malignancy are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Not Applicable with 20 trials, with the heaviest enrollment activity in Boston, Memphis, and New York. Lead sponsors running hematologic malignancy studies include St. Jude Children's Research Hospital, Massachusetts General Hospital, and Duke University.

Browse hematologic malignancy trials by phase

Treatments under study

About Hematologic Malignancy Clinical Trials

Looking for clinical trials for Hematologic Malignancy? There are currently 70 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematologic Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematologic Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 78 trials

Recruiting

Response to Influenza Vaccination in Pediatric Oncology Patients

Hematologic MalignancyPediatric CancerTransplant-Related Cancer
St. Jude Children's Research Hospital150 enrolled1 locationNCT05384288
Recruiting
Phase 3

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Solid TumorHematologic MalignancyAdvanced Malignancies
Novartis Pharmaceuticals50 enrolled15 locationsNCT06401356
Recruiting

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Solid TumorHematologic MalignancyB-ALL
St. Jude Children's Research Hospital100 enrolled5 locationsNCT06579469
Recruiting
Phase 1Phase 2

Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.

Solid TumorHematologic Malignancy
Chinese PLA General Hospital24 enrolled1 locationNCT07570563
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Hematologic Malignancy
St. Jude Children's Research Hospital30 enrolled1 locationNCT07052370
Recruiting
Not Applicable

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

Solid TumorHematologic MalignancySickle Cell Disease+3 more
Washington University School of Medicine60 enrolled1 locationNCT06689800
Recruiting

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

LymphomaLeukemiaHematologic Malignancy
National Cancer Institute (NCI)88 enrolled1 locationNCT06856226
Recruiting

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Relapsed Hematologic MalignancyRefractory Hematologic Malignancy
St. Jude Children's Research Hospital1,000 enrolled1 locationNCT05713214
Recruiting

Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy

CancerHematologic Malignancy
University Hospital, Lille700 enrolled2 locationsNCT07609485
Recruiting
Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Hematologic MalignancyRelapsed Pediatric ALLHematopoietic Cell Transplantation
St. Jude Children's Research Hospital70 enrolled1 locationNCT07257419
Recruiting

Global Cardio Oncology Registry

Breast CancerCardiotoxicityCardiovascular Diseases+2 more
The Cleveland Clinic5,000 enrolled1 locationNCT05598879
Recruiting
Phase 1

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Diffuse Large B Cell LymphomaAcute Lymphoblastic LeukemiaMultiple Myeloma+3 more
Joshua Sasine, MD, PhD20 enrolled1 locationNCT05887167
Recruiting
Not Applicable

Expressive Writing Program Among Young Adults With Blood Cancer

Hematologic Malignancy
Blood Cancer United100 enrolled1 locationNCT07413991
Recruiting
Phase 2

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Non-Hodgkin LymphomaHematologic MalignancyMantle Cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05529069
Recruiting
Not Applicable

Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment

Hematologic Malignancy
Duke University60 enrolled1 locationNCT06532773
Recruiting
Not Applicable

Allergy Delabeling in Antibiotic Stewardship - Intervention

Hematologic MalignancyBeta Lactam Allergy
Ebbing Lautenbach3,800 enrolled1 locationNCT07133074
Recruiting
Not Applicable

Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation

Hematologic MalignancyHematopoietic Cell Transplant
Massachusetts General Hospital40 enrolled1 locationNCT06676852
Recruiting
Not Applicable

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Multiple MyelomaLymphomaLeukemia+2 more
Massachusetts General Hospital90 enrolled1 locationNCT05646576
Recruiting
Phase 1Phase 2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078